BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184-2196. [PMID: 31813633 DOI: 10.1016/s0140-6736(19)33041-7] [Cited by in Crossref: 493] [Cited by in F6Publishing: 430] [Article Influence: 123.3] [Reference Citation Analysis]
Number Citing Articles
1 Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol 2023;8:120-32. [PMID: 36521501 DOI: 10.1016/S2468-1253(22)00347-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wu Y, Jin X, Zhang Y, Liu J, Wu M, Tong H. Bioactive Compounds from Brown Algae Alleviate Nonalcoholic Fatty Liver Disease: An Extensive Review. J Agric Food Chem 2023;71:1771-87. [PMID: 36689477 DOI: 10.1021/acs.jafc.2c06578] [Reference Citation Analysis]
3 Guo Y, Xie G, Zhang X. Role of FXR in Renal Physiology and Kidney Diseases. IJMS 2023;24:2408. [DOI: 10.3390/ijms24032408] [Reference Citation Analysis]
4 Dahmus J, Hummer B, Rivas G, Schmitz K, Caldwell SH, Argo CK, Schreibman I, Stine JG. Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness. Dig Dis Sci 2023. [PMID: 36692803 DOI: 10.1007/s10620-022-07809-w] [Reference Citation Analysis]
5 Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, Xu S, Tang D, Jiao Y, Yang L, Yu W, Gao P. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1078149] [Reference Citation Analysis]
6 Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum 2023;59:152165. [PMID: 36716599 DOI: 10.1016/j.semarthrit.2023.152165] [Reference Citation Analysis]
7 Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 2022;13:1087260. [PMID: 36726464 DOI: 10.3389/fendo.2022.1087260] [Reference Citation Analysis]
8 Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, Rinaldi L, Marfella R, Sasso FC. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci 2023;24. [PMID: 36675217 DOI: 10.3390/ijms24021703] [Reference Citation Analysis]
9 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
10 Barcelos STA, Silva-Sperb AS, Moraes HA, Longo L, de Moura BC, Michalczuk MT, Uribe-Cruz C, Cerski CTS, da Silveira TR, Dall'Alba V, Álvares-da-Silva MR. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Ann Hepatol 2023;28:100769. [PMID: 36216309 DOI: 10.1016/j.aohep.2022.100769] [Reference Citation Analysis]
11 Ntona S, Papaefthymiou A, Kountouras J, Gialamprinou D, Kotronis G, Boziki M, Polyzos SA, Tzitiridou M, Chatzopoulos D, Thavayogarajah T, Gkolia I, Ntonas G, Vardaka E, Doulberis M. Impact of nonalcoholic fatty liver disease-related metabolic state on depression. Neurochem Int 2023;163:105484. [PMID: 36634820 DOI: 10.1016/j.neuint.2023.105484] [Reference Citation Analysis]
12 de Assis LVM, Demir M, Oster H. The role of the circadian clock in the development, progression, and treatment of non-alcoholic fatty liver disease. Acta Physiol (Oxf) 2023;:e13915. [PMID: 36599410 DOI: 10.1111/apha.13915] [Reference Citation Analysis]
13 Pan Y, Zhang X. Diet Modulates Gut Microbiome and Metabolites in Non-alcoholic Fatty Liver Diseases. Microbiome in Gastrointestinal Cancer 2023. [DOI: 10.1007/978-981-19-4492-5_9] [Reference Citation Analysis]
14 van Son KC, (Onno) Holleboom A, Tushuizen ME. Nonalcoholic fatty liver disease. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00024-9] [Reference Citation Analysis]
15 Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol 2023;35:1-14. [PMID: 36468565 DOI: 10.1097/MEG.0000000000002471] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Manoharan N, Parasuraman R, Jayamurali D, Govindarajulu SN. The therapeutic role of microbial metabolites in human health and diseases. Recent Advances and Future Perspectives of Microbial Metabolites 2023. [DOI: 10.1016/b978-0-323-90113-0.00002-x] [Reference Citation Analysis]
17 Wiering L, Tacke F. Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol 2023;256:e220194. [PMID: 36259984 DOI: 10.1530/JOE-22-0194] [Reference Citation Analysis]
18 Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, Tsai WW, Mahadevan S, Minto W, Diehl L, Gupta R, Trauner M, Patel K, Noureddin M, Kowdley KV, Gulamhusein A, Bowlus CL, Huss RS, Myers RP, Chung C, Billin AN. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology 2023;77:20-32. [PMID: 35686937 DOI: 10.1002/hep.32599] [Reference Citation Analysis]
19 Lee EJ, Kim Y, Kim JE, Yoon EL, Lee SR, Jun DW. ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model. Life (Basel) 2022;13. [PMID: 36676050 DOI: 10.3390/life13010100] [Reference Citation Analysis]
20 Moreau F, Brunao BB, Liu XY, Tremblay F, Fitzgerald K, Avila-Pacheco J, Clish C, Kahn RC, Softic S. Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis. J Lipid Res 2022;64:100324. [PMID: 36586437 DOI: 10.1016/j.jlr.2022.100324] [Reference Citation Analysis]
21 Zhang W, Shi B, Li S, Liu Z, Li S, Dong S, Cheng Y, Zhu J, Zhang G, Zhong M. Sleeve gastrectomy improves lipid dysmetabolism by downregulating the USP20-HSPA2 axis in diet-induced obese mice. Front Endocrinol (Lausanne) 2022;13:1041027. [PMID: 36636478 DOI: 10.3389/fendo.2022.1041027] [Reference Citation Analysis]
22 Jirapinyo P, Zucker SD, Thompson CC. Regression of Hepatic Fibrosis Following Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2022. [PMID: 36597405 DOI: 10.14309/ajg.0000000000002087] [Reference Citation Analysis]
23 Zhuge A, Li S, Yuan Y, Han S, Xia J, Wang Q, Wang S, Lou P, Li B, Li L. Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. Redox Biol 2023;59:102582. [PMID: 36584600 DOI: 10.1016/j.redox.2022.102582] [Reference Citation Analysis]
24 Chen JYS, Chua D, Lim CO, Ho WX, Tan NS. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. Int J Mol Sci 2022;24. [PMID: 36613602 DOI: 10.3390/ijms24010158] [Reference Citation Analysis]
25 Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers (Basel) 2022;15. [PMID: 36612019 DOI: 10.3390/cancers15010023] [Reference Citation Analysis]
26 Malnick SDH, Alin P, Somin M, Neuman MG. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. Int J Mol Sci 2022;23. [PMID: 36555867 DOI: 10.3390/ijms232416226] [Reference Citation Analysis]
27 Li S, Zhuge A, Wang K, Xia J, Wang Q, Han S, Shen J, Li L. Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. Front Pharmacol 2022;13:1081553. [PMID: 36588706 DOI: 10.3389/fphar.2022.1081553] [Reference Citation Analysis]
28 Guo F, Gao Y, Li X, Lei X. Natural Product 2-Oxokolavenol Is a Novel FXR Agonist. Molecules 2022;27. [PMID: 36558100 DOI: 10.3390/molecules27248968] [Reference Citation Analysis]
29 Bing H, Li YL. The role of bile acid metabolism in the occurrence and development of NAFLD. Front Mol Biosci 2022;9:1089359. [PMID: 36589245 DOI: 10.3389/fmolb.2022.1089359] [Reference Citation Analysis]
30 Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, Biegel H, Kowdley KV, Chalasani N, Dasarathy S, Diehl AM, Loomba R, Hameed B, Behling C, Kleiner DE, Karpen SJ, Williams J, Jia Y, Yates KP, Tonascia J. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol 2022:S0168-8278(22)03326-8. [PMID: 36528237 DOI: 10.1016/j.jhep.2022.11.029] [Reference Citation Analysis]
31 Erlinger S. A history of research into the physiology of bile, from Hippocrates to molecular medicine. Clin Liver Dis (Hoboken) 2022;20:33-44. [PMID: 36518787 DOI: 10.1002/cld.1266] [Reference Citation Analysis]
32 Herta T, Beuers U. A historical review of jaundice: May the golden oriole live forever. Clin Liver Dis (Hoboken) 2022;20:45-56. [PMID: 36518790 DOI: 10.1002/cld.1267] [Reference Citation Analysis]
33 Liu SY, Huang CC, Yang YY, Huang SF, Lee TY, Li TH, Hou MC, Lin HC. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. PLoS One 2022;17:e0276717. [PMID: 36490253 DOI: 10.1371/journal.pone.0276717] [Reference Citation Analysis]
34 Guo F, Chen K, Dong H, Hu D, Gao Y, Liu C, Laphookhieo S, Lei X. Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-Fargesone A as a Novel FXR Agonist. JACS Au 2022;2:2830-8. [PMID: 36590256 DOI: 10.1021/jacsau.2c00600] [Reference Citation Analysis]
35 Guo J, Shi CX, Zhang QQ, Deng W, Zhang LY, Chen Q, Zhang DM, Gong ZJ. Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective. Therap Adv Gastroenterol 2022;15:17562848221138676. [PMID: 36506748 DOI: 10.1177/17562848221138676] [Reference Citation Analysis]
36 Xu W, Cui C, Cui C, Chen Z, Zhang H, Cui Q, Xu G, Fan J, Han Y, Tang L, Targher G, Byrne CD, Zheng MH, Yang L, Cai J, Geng B. Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. Hepatology 2022;76:1794-810. [PMID: 35586979 DOI: 10.1002/hep.32577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Chen Q, Yi J, Liu F, Li J, Lu K, Wang X, Zhang F, Li Y, Wu L, Yang X, Lu S, Li D. TGF-β1 contributes to the hepatic inflammation in animal models with nonalcoholic steatohepatitis by Smad3/TLR2 signaling pathway. Molecular Immunology 2022;152:129-139. [DOI: 10.1016/j.molimm.2022.10.014] [Reference Citation Analysis]
38 Che W, Zhao M, Li X, Li C, Cho WC, Yu S. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Front Endocrinol (Lausanne) 2022;13:1002916. [PMID: 36523601 DOI: 10.3389/fendo.2022.1002916] [Reference Citation Analysis]
39 Kamiya A, Ida K. Liver Injury and Cell Survival in Non-Alcoholic Steatohepatitis Regulated by Sex-Based Difference through B Cell Lymphoma 6. Cells 2022;11. [PMID: 36497010 DOI: 10.3390/cells11233751] [Reference Citation Analysis]
40 Di Ciaula A, Bonfrate L, Baj J, Khalil M, Garruti G, Stellaard F, Wang HH, Wang DQ, Portincasa P. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Nutrients 2022;14. [PMID: 36500979 DOI: 10.3390/nu14234950] [Reference Citation Analysis]
41 Tay PWL, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Tan DJH, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. Am J Gastroenterol 2022. [PMID: 36191268 DOI: 10.14309/ajg.0000000000002042] [Reference Citation Analysis]
42 Lee SM, Jun DW, Yoon EL, Oh JH, Roh YJ, Lee EJ, Shin J, Nam Y, Kim HS. Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease.. [DOI: 10.21203/rs.3.rs-2257825/v1] [Reference Citation Analysis]
43 Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol 2022:S0168-8278(22)03160-9. [PMID: 36334688 DOI: 10.1016/j.jhep.2022.10.023] [Reference Citation Analysis]
44 Fang J, Yu C, Li X, Yao J, Fang Z, Yoon S, Yu W. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.997018] [Reference Citation Analysis]
45 Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251 [DOI: 10.12998/wjcc.v10.i31.11240] [Reference Citation Analysis]
46 Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, Zhang K, Li W, Chen W, Zhao S, Li Y, Ye W. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.973366] [Reference Citation Analysis]
47 Hou T, Tian Y, Cao Z, Zhang J, Feng T, Tao W, Sun H, Wen H, Lu X, Zhu Q, Li M, Lu X, Liu B, Zhao Y, Yang Y, Zhu W. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. Molecular Cell 2022;82:4099-4115.e9. [DOI: 10.1016/j.molcel.2022.09.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, Bhasin K, Jones BA, Orlicky DJ, Takahashi S, Dvornikov A, Kleiner DE, Hewitt SM, Adorini L, Kopp JB, Krausz KW, Rosenberg A, Mcmanaman JL, Robertson CE, Ir D, Frank DN, Luo Y, Gonzalez FJ, Gratton E, Levi M. The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice. Journal of Biological Chemistry 2022;298:102530. [DOI: 10.1016/j.jbc.2022.102530] [Reference Citation Analysis]
49 Zhang Y, Dalamaga M, Liu J. Targeting MRG15 for the treatment of nonalcoholic steatohepatitis. Metabolism Open 2022. [DOI: 10.1016/j.metop.2022.100217] [Reference Citation Analysis]
50 Matye DJ, Qin X, Hasan MN, Gu L, Clayton Y, Li F, Li T. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis. Liver Research 2022. [DOI: 10.1016/j.livres.2022.11.002] [Reference Citation Analysis]
51 Kim M, Lee S, Randolph G, Han Y. Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.121176] [Reference Citation Analysis]
52 Koda Y, Nakamoto N, Kanai T. Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells. Semin Liver Dis 2022;42:475-88. [PMID: 36208620 DOI: 10.1055/a-1957-6384] [Reference Citation Analysis]
53 Huang DQ, Downes M, Evans RM, Witztum JL, Glass CK, Loomba R. Shared Mechanisms between Cardiovascular Disease and NAFLD. Semin Liver Dis 2022;42:455-64. [PMID: 36008083 DOI: 10.1055/a-1930-6658] [Reference Citation Analysis]
54 Phung HH, Lee CH. Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Arch Pharm Res 2022. [DOI: 10.1007/s12272-022-01410-5] [Reference Citation Analysis]
55 Chen B, Tang WHW, Rodriguez M, Corey KE, Sanyal AJ, Kamath PS, Bozkurt B, Virk HUH, Pressman GS, Lazarus JV, El-Serag HB, Krittanawong C. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? Semin Liver Dis 2022;42:465-74. [PMID: 36241194 DOI: 10.1055/s-0042-1757712] [Reference Citation Analysis]
56 Brennan PN, Dillon JF, McCrimmon R. Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. touchREV Endocrinol 2022;18:148-55. [PMID: 36694893 DOI: 10.17925/EE.2022.18.2.148] [Reference Citation Analysis]
57 Zhang D, Zhang Y, Sun B. The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. IJMS 2022;23:12572. [DOI: 10.3390/ijms232012572] [Reference Citation Analysis]
58 Garbuzenko DV. Current strategies for targeted therapy of liver fibrosis. Bûll sib med 2022;21:154-165. [DOI: 10.20538/1682-0363-2022-3-154-165] [Reference Citation Analysis]
59 Li G, Wong GL, Yip TC, Tan Q, Lin H, Wilson JM, Bowsman LM, Haas JV, Chan AW, Leung HH, Zhang X, Tse Y, Shu SS, Chim AM, Chan HL, Yuen PC, Wong VW, Duffin KL, Chen Y. A Sequential Machine Learning Model for Identifying At-risk NASH by Combining Liver Stiffness Measurement and Protein Biomarkers.. [DOI: 10.21203/rs.3.rs-2118271/v1] [Reference Citation Analysis]
60 Wang M, Li L, Xu Y, Du J, Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol 2022;13:958428. [DOI: 10.3389/fphar.2022.958428] [Reference Citation Analysis]
61 Ortiz-lópez N, Fuenzalida C, Dufeu MS, Pinto-león A, Escobar A, Poniachik J, Roblero JP, Valenzuela-pérez L, Beltrán CJ. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 2022;13:954869. [DOI: 10.3389/fimmu.2022.954869] [Reference Citation Analysis]
62 Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, Yan B, Magagna J, Beiriger J, Shah Y, Shahzad T, Halegoua-demarzio D. Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). Livers 2022;2:264-282. [DOI: 10.3390/livers2040022] [Reference Citation Analysis]
63 Wetten A, Jones DEJ, Dyson JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Expert Opin Investig Drugs 2022;:1-7. [PMID: 36194037 DOI: 10.1080/13543784.2022.2130750] [Reference Citation Analysis]
64 Zheng M, Okawa S, Bravo M, Chen F, Martínez-Chantar ML, Del Sol A. ChemPert: mapping between chemical perturbation and transcriptional response for non-cancer cells. Nucleic Acids Res 2023;51:D877-89. [PMID: 36200827 DOI: 10.1093/nar/gkac862] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Floreani A, Gabbia D, De Martin S. Obeticholic Acid for Primary Biliary Cholangitis. Biomedicines 2022;10:2464. [PMID: 36289726 DOI: 10.3390/biomedicines10102464] [Reference Citation Analysis]
66 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022;71:2123-34. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
67 Röhlen N, Thimme R, Böttler T. Leberfibrose - Diagnostik und innovative Therapieansätze. Gastro-News 2022;9:40-50. [DOI: 10.1007/s15036-022-3108-8] [Reference Citation Analysis]
68 Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 2022;76:1121-34. [PMID: 35220605 DOI: 10.1002/hep.32427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
69 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022;77:1136-60. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
70 Romero-gómez M. Non-alcoholic steatohepatitis. Medicina Clínica (English Edition) 2022;159:388-395. [DOI: 10.1016/j.medcle.2022.09.004] [Reference Citation Analysis]
71 Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [DOI: 10.4254/wjh.v14.i9.1718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Mandour MO, El-Hassan M, Elkomi RM, Oben JA. Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future? World J Hepatol 2022; 14(9): 1704-1717 [DOI: 10.4254/wjh.v14.i9.1704] [Reference Citation Analysis]
73 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
74 Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00370-2] [Reference Citation Analysis]
75 Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2022;5:e2230426. [PMID: 36098969 DOI: 10.1001/jamanetworkopen.2022.30426] [Reference Citation Analysis]
76 Romero-Gómez M. Non-alcoholic steatohepatitis. Med Clin (Barc) 2022:S0025-7753(22)00403-1. [PMID: 36075749 DOI: 10.1016/j.medcli.2022.06.017] [Reference Citation Analysis]
77 Authors, Collaborators:. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025. Z Gastroenterol 2022;60:e733-e801. [DOI: 10.1055/a-1880-2388] [Reference Citation Analysis]
78 Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators:. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022;60:1346-421. [PMID: 36100202 DOI: 10.1055/a-1880-2283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
79 Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol 2022;20:2050-2058.e12. [PMID: 34274514 DOI: 10.1016/j.cgh.2021.07.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
80 Marzano M, Fosso B, Colliva C, Notario E, Passeri D, Intranuovo M, Gioiello A, Adorini L, Pesole G, Pellicciari R, Moschetta A, Gadaleta R. Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow. Biomedicine & Pharmacotherapy 2022;153:113380. [DOI: 10.1016/j.biopha.2022.113380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol 2022;77:607-18. [PMID: 35439567 DOI: 10.1016/j.jhep.2022.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
82 Lake‐bakaar G, Robertson J, Aardema C. The effect of obeticholic acid on hepatic blood flow in isolated, perfused porcine liver: Correction of oxygen‐nutrient mismatch might be a putative mechanism of action in NASH. Clinical and Translational Dis 2022;2. [DOI: 10.1002/ctd2.98] [Reference Citation Analysis]
83 Basu R, Noureddin M, Clark JM. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clin Proc 2022;97:1700-16. [PMID: 36058582 DOI: 10.1016/j.mayocp.2022.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Aishwarya TS, Mounika N, Vishwakarma G, Adela R. Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis. RPS Pharmacy and Pharmacology Reports 2022;1. [DOI: 10.1093/rpsppr/rqac001] [Reference Citation Analysis]
85 Labenz C, Arslanow A, Nguyen-Tat M, Nagel M, Wörns MA, Reichert MC, Heil FJ, Mainz D, Zimper G, Römer B, Binder H, Farin-Glattacker E, Fichtner U, Graf E, Stelzer D, Van Ewijk R, Ortner J, Velthuis L, Lammert F, Galle PR. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. J Hepatol 2022;77:695-701. [PMID: 35472313 DOI: 10.1016/j.jhep.2022.04.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
86 Liu J, Wu A, Cai J, She Z, Li H. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD. Front Immunol 2022;13:968799. [DOI: 10.3389/fimmu.2022.968799] [Reference Citation Analysis]
87 Zhou C, Zhang W, Lin H, Zhang L, Wu F, Wang Y, Yu S, Peng X, Cheng W, Li M, Pan X, Huang Z, Zhang W. Effect of theaflavin-3,3′-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota. Front Pharmacol 2022;13:925264. [DOI: 10.3389/fphar.2022.925264] [Reference Citation Analysis]
88 Wang J, Lou C, Liu G, Li W, Wu Z, Tang Y. Profiling prediction of nuclear receptor modulators with multi-task deep learning methods: toward the virtual screening. Brief Bioinform 2022:bbac351. [PMID: 35998896 DOI: 10.1093/bib/bbac351] [Reference Citation Analysis]
89 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
90 Arredouani A. Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. Lifestyle-Related Diseases and Metabolic Syndrome [Working Title] 2022. [DOI: 10.5772/intechopen.106445] [Reference Citation Analysis]
91 Li Y, Wang K, Ding J, Sun S, Ni Z, Yu C. Influence of the gut microbiota on endometriosis: Potential role of chenodeoxycholic acid and its derivatives. Front Pharmacol 2022;13:954684. [DOI: 10.3389/fphar.2022.954684] [Reference Citation Analysis]
92 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
93 Liu Y, Liu T, Zhao X, Gao Y. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease. Cell Mol Life Sci 2022;79:486. [PMID: 35978227 DOI: 10.1007/s00018-022-04509-6] [Reference Citation Analysis]
94 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
95 Shrestha A, Pradhananga S. Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. Euroasian Journal of Hepato-Gastroenterology 2022;12:S51-S58. [DOI: 10.5005/jp-journals-10018-1359] [Reference Citation Analysis]
96 Cui S, Hu H, Chen A, Cui M, Pan X, Zhang P, Wang G, Wang H, Hao H. SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.019] [Reference Citation Analysis]
97 Pais R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, Oppert JM, Siksik JM, Genser L, Charlotte F, Thabut D, Clement K, Ratziu V. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology 2022;76:456-68. [PMID: 35076966 DOI: 10.1002/hep.32358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Pattou F, Lasailly G, Raverdy V, Caiazzo R, Mathurin P. Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty. Hepatology 2022;76:E51-2. [PMID: 35395102 DOI: 10.1002/hep.32516] [Reference Citation Analysis]
99 Peng Y, Yin Q, Yuan M, Chen L, Shen X, Xie W, Liu J. Role of hepatic stellate cells in liver ischemia-reperfusion injury. Front Immunol 2022;13:891868. [DOI: 10.3389/fimmu.2022.891868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Vander Does A, Levy C, Yosipovitch G. Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. Am J Clin Dermatol 2022. [PMID: 35900649 DOI: 10.1007/s40257-022-00710-2] [Reference Citation Analysis]
101 Heath L, Aveyard P, Tomlinson JW, Cobbold JF, Koutoukidis DA. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. Hepatol Commun 2022. [PMID: 35903833 DOI: 10.1002/hep4.2044] [Reference Citation Analysis]
102 Zhou L, Shen H, Li X, Wang H. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease. Front Immunol 2022;13:951406. [DOI: 10.3389/fimmu.2022.951406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Wang Z, Ye M, Zhang XJ, Zhang P, Cai J, Li H, She ZG. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 2022;355:30-44. [PMID: 35872444 DOI: 10.1016/j.atherosclerosis.2022.07.010] [Reference Citation Analysis]
104 Makri ES, Makri E, Polyzos SA. Combination Therapies for Nonalcoholic Fatty Liver Disease. JPM 2022;12:1166. [DOI: 10.3390/jpm12071166] [Reference Citation Analysis]
105 Ye X, Zhang T, Han H. PPARα: A potential therapeutic target of cholestasis. Front Pharmacol 2022;13:916866. [DOI: 10.3389/fphar.2022.916866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
107 Shao G, Liu Y, Lu L, Zhang G, Zhou W, Wu T, Wang L, Xu H, Ji G. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Front Pharmacol 2022;13:944088. [DOI: 10.3389/fphar.2022.944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
109 Lee AH, Manly A, Dong TS. Leveraging the Microbiome for Obesity: Moving From Form to Function. Front Endocrinol 2022;13:918923. [DOI: 10.3389/fendo.2022.918923] [Reference Citation Analysis]
110 Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol 2022;19:432-50. [PMID: 35165436 DOI: 10.1038/s41575-021-00566-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
111 Cho YE, Kwon YS, Hwang S. Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.06.001] [Reference Citation Analysis]
112 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. J Hepatol 2022;77:219-36. [PMID: 35157957 DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
113 Gracia-Sancho J, Dufour JF. NTCP: a pharmacological target for multiple liver conditions. Gut 2022;71:1248-50. [PMID: 34857616 DOI: 10.1136/gutjnl-2021-325917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, Zhang B, Yang J, Yao Y. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther 2022;7:206. [PMID: 35773269 DOI: 10.1038/s41392-022-01070-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
115 Di Vincenzo F, Puca P, Lopetuso LR, Petito V, Masi L, Bartocci B, Murgiano M, De Felice M, Petronio L, Gasbarrini A, Scaldaferri F. Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis. Nutrients 2022;14:2664. [DOI: 10.3390/nu14132664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A, Boehm S, Zhao Q, Krupinski J, Charles ED, Zinker B, Tacke F. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. Int J Mol Sci 2022;23:6696. [PMID: 35743140 DOI: 10.3390/ijms23126696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
117 Nara SJ, Jogi S, Cheruku S, Kandhasamy S, Jaipuri F, Kathi PK, Reddy S, Sarodaya S, Cook EM, Wang T, Sitkoff D, Rossi KA, Ruzanov M, Kiefer SE, Khan JA, Gao M, Reddy S, Sivaprasad Lvj S, Sane R, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara A, Krupinski J, Soars MG, Ellsworth BA, Wacker DA. Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2022. [PMID: 35704802 DOI: 10.1021/acs.jmedchem.2c00165] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
118 Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12:824. [PMID: 35740949 DOI: 10.3390/biom12060824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
119 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Lefever DE, Miedel MT, Pei F, DiStefano JK, Debiasio R, Shun TY, Saydmohammed M, Chikina M, Vernetti LA, Soto-Gutierrez A, Monga SP, Bataller R, Behari J, Yechoor VK, Bahar I, Gough A, Stern AM, Taylor DL. A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies. Metabolites 2022;12:528. [PMID: 35736460 DOI: 10.3390/metabo12060528] [Reference Citation Analysis]
121 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
122 Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology 2022;75:1647-61. [PMID: 34990037 DOI: 10.1002/hep.32315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
124 Wallace SJ, Tacke F, Schwabe RF, Henderson NC. Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Spiers J, Brindley JH, Li W, Alazawi W. What's new in non-alcoholic fatty liver disease? Frontline Gastroenterol 2022;13:e102-8. [PMID: 35812024 DOI: 10.1136/flgastro-2022-102122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
126 Guo Y, Peng Q, Hao L, Ji J, Zhang Z, Xue Y, Liu Y, Gao Y, Li C, Shi X. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma. FASEB J 2022;36:e22361. [PMID: 35616366 DOI: 10.1096/fj.202200171R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Cao Y, Mai W, Li R, Deng S, Li L, Zhou Y, Qin Q, Zhang Y, Zhou X, Han M, Liang P, Yan Y, Hao Y, Xie W, Yan J, Zhu L. Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway. Cell Mol Life Sci 2022;79:303. [PMID: 35588334 DOI: 10.1007/s00018-022-04319-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
128 Luo W, Guo S, Zhou Y, Zhao J, Wang M, Sang L, Chang B, Wang B. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Front Microbiol 2022;13:873160. [PMID: 35572649 DOI: 10.3389/fmicb.2022.873160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Lin C, Yu B, Chen L, Zhang Z, Ye W, Zhong H, Bai W, Yang Y, Nie B. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice. Front Pharmacol 2022;13:880508. [DOI: 10.3389/fphar.2022.880508] [Reference Citation Analysis]
130 Ahmed NR, Kulkarni VV, Pokhrel S, Akram H, Abdelgadir A, Chatterjee A, Khan S. Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. Cureus. [DOI: 10.7759/cureus.24829] [Reference Citation Analysis]
131 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
133 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Panzitt K, Zollner G, Marschall H, Wagner M. Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 2022;71:983-90. [PMID: 33883248 DOI: 10.1136/gutjnl-2021-324264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
136 Marjot T, Ray DW, Tomlinson JW. Is it time for chronopharmacology in NASH? J Hepatol 2022;76:1215-24. [PMID: 35066087 DOI: 10.1016/j.jhep.2021.12.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
137 Chan WK, Tan SS, Chan SP, Lee YY, Tee HP, Mahadeva S, Goh KL, Ramli AS, Mustapha F, Kosai NR, Raja Ali RA. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol 2022;37:795-811. [PMID: 35080048 DOI: 10.1111/jgh.15787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Zheng M, Okawa S, Bravo M, Chen F, Martínez-chantar M, del Sol A. ChemPert: mapping between chemical perturbation and transcriptional response for non-cancer cells.. [DOI: 10.1101/2022.04.29.490084] [Reference Citation Analysis]
139 Tian SY, Chen SM, Pan CX, Li Y. FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin 2022;43:1120-32. [PMID: 35217809 DOI: 10.1038/s41401-021-00849-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
140 Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2022;54:598-613. [PMID: 34344577 DOI: 10.1016/j.dld.2021.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
141 Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076-87. [PMID: 35285529 DOI: 10.1111/apt.16808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
142 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
143 Guan B, Tong J, Hao H, Yang Z, Chen K, Xu H, Wang A. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sin B 2022;12:2129-49. [PMID: 35646540 DOI: 10.1016/j.apsb.2021.12.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
144 Griffett K, Hayes ME, Boeckman MP, Burris TP. The role of REV-ERB in NASH. Acta Pharmacol Sin 2022;43:1133-40. [PMID: 35217816 DOI: 10.1038/s41401-022-00883-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
146 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2022;54:583-97. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
148 Tang S, Mao X, Chen Y, Yan L, Ye L, Li S. Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death. Front Immunol 2022;13:870239. [DOI: 10.3389/fimmu.2022.870239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
149 Li X, Zhao W, Xiao M, Yu L, Chen Q, Hu X, Zhao Y, Xiong L, Chen X, Wang X, Ba Y, Guo Q, Wu X. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. J Ethnopharmacol 2022;:115333. [PMID: 35500802 DOI: 10.1016/j.jep.2022.115333] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 Neri CR, Scapaticci S, Chiarelli F, Giannini C. Liver Steatosis: A Marker of Metabolic Risk in Children. Int J Mol Sci 2022;23:4822. [PMID: 35563210 DOI: 10.3390/ijms23094822] [Reference Citation Analysis]
151 Fiorucci S, Zampella A, Ricci P, Distrutti E, Biagioli M. Immunomodulatory functions of FXR. Mol Cell Endocrinol 2022;551:111650. [PMID: 35472625 DOI: 10.1016/j.mce.2022.111650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
152 Ampuero J. General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. Clin Drug Investig 2022. [PMID: 35467297 DOI: 10.1007/s40261-022-01142-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarathy S, Vuppalanchi R, Siddiqui MS, Kowdley KV, McCullough A, Terrault NA, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One 2022;17:e0266859. [PMID: 35427375 DOI: 10.1371/journal.pone.0266859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Chung KW, Cho YE, Kim SJ, Hwang S. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Arch Pharm Res 2022. [PMID: 35391713 DOI: 10.1007/s12272-022-01379-1] [Reference Citation Analysis]
156 Li R, Hovingh MV, Koehorst M, de Blaauw P, Verkade HJ, de Boer JF, Kuipers F. Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022. [DOI: 10.1016/j.bbalip.2022.159163] [Reference Citation Analysis]
157 Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian J Gastroenterol 2022;41:169-80. [PMID: 35279807 DOI: 10.1007/s12664-021-01220-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
159 Tang Y, Yin X, Ma Y. Non-Alcoholic Fatty Liver Disease and Its Potential Therapeutic Strategies. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.103059] [Reference Citation Analysis]
160 Osipova D, Kokoreva K, Lazebnik L, Golovanova E, Pavlov C, Dukhanin A, Orlova S, Starostin K. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved. Front Pharmacol 2022;13:797923. [DOI: 10.3389/fphar.2022.797923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Zhang T, Feng S, Li J, Wu Z, Deng Q, Yang W, Li J, Pan G. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway. Arch Toxicol 2022. [PMID: 35267068 DOI: 10.1007/s00204-022-03266-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Berry P, Kotha S. The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease. EMJ Hepatol 2022. [DOI: 10.33590/emjhepatol/21-00217] [Reference Citation Analysis]
163 Rowe IA, Parker R. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. Clin Gastroenterol Hepatol 2022;20:e564-72. [PMID: 34091047 DOI: 10.1016/j.cgh.2021.05.059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
164 Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2022;76:536-48. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
165 Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2022;76:506-17. [PMID: 34740705 DOI: 10.1016/j.jhep.2021.10.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
166 Jiang L, Liu X, Wei H, Dai S, Qu L, Chen X, Guo M, Chen Y. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor. Biochemical and Biophysical Research Communications 2022;595:1-6. [DOI: 10.1016/j.bbrc.2022.01.069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
168 Uehara K, Sostre-Colón J, Gavin M, Santoleri D, Leonard KA, Jacobs RL, Titchenell PM. Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. Cell Mol Gastroenterol Hepatol 2022;13:1625-47. [PMID: 35240344 DOI: 10.1016/j.jcmgh.2022.02.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
169 Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
170 Zhang Q, Zhang L, Liu K, Shang H, Ruan J, Yu Z, Meng S, Liang F, Wang T, Zhang H, Peng W, Wang Y, Chen J, Xiao T, Wang B. A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2022;2022:1638740. [PMID: 35178098 DOI: 10.1155/2022/1638740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
172 Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J. Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines 2022;10:451. [DOI: 10.3390/biomedicines10020451] [Reference Citation Analysis]
173 Uehara K, Titchenell PM. Curing Fatty Liver with Oxysterols? Cell Mol Gastroenterol Hepatol 2022;13:1265-6. [PMID: 35167817 DOI: 10.1016/j.jcmgh.2022.01.020] [Reference Citation Analysis]
174 Gay MD, Cao H, Shivapurkar N, Dakshanamurthy S, Kallakury B, Tucker RD, Kwagyan J, Smith JP. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. Int J Mol Sci 2022;23. [PMID: 35163821 DOI: 10.3390/ijms23031899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
175 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
176 Trivedi HD, Suri J, Oh D, Schwartz J, Goyes D, Idriss R, Curry MP, Lai M. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Ann Hepatol 2021;24:100336. [PMID: 33647502 DOI: 10.1016/j.aohep.2021.100336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2022;54:170-82. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
178 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
179 Hoebinger C, Rajcic D, Hendrikx T. Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis. Front Cardiovasc Med 2021;8:824481. [PMID: 35083304 DOI: 10.3389/fcvm.2021.824481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
180 Zhao M, Xie H, Shan H, Zheng Z, Li G, Li M, Hong L. Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:1102. [PMID: 35163026 DOI: 10.3390/ijms23031102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
181 Wang L, Li M, Yu B, Shi S, Liu J, Zhang R, Ayada I, Verstegen MMA, van der Laan LJW, Peppelenbosch MP, Cao W, Pan Q. Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. J Mol Med. [DOI: 10.1007/s00109-021-02176-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Wang LX, Frey MR, Kohli R. The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. Front Endocrinol 2022;12:799648. [DOI: 10.3389/fendo.2021.799648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
183 Roeb E, Nitschmann S. [News on non-alcoholic steatohepatitis]. Internist (Berl) 2022. [PMID: 35024879 DOI: 10.1007/s00108-022-01261-8] [Reference Citation Analysis]
184 Kumari B, Sharma S, Kumar R, Dipankar S, Naik BN, Banerjee A, Kumar S. Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Cureus 2022. [DOI: 10.7759/cureus.21110] [Reference Citation Analysis]
185 Luo Y, Decato BE, Charles ED, Shevell DE, McNaney C, Shipkova P, Apfel A, Tirucherai GS, Sanyal AJ. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. JHEP Rep 2022;4:100392. [PMID: 34977519 DOI: 10.1016/j.jhepr.2021.100392] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Garbuzenko DV. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;31:16-24. [DOI: 10.22416/1382-4376-2021-31-5-16-24] [Reference Citation Analysis]
187 F. Lange N, Dufour J. Spezifische Therapie – neue Medikamente. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_21] [Reference Citation Analysis]
188 Albhaisi S, Sanyal AJ. Pharmacology of NASH. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00121-3] [Reference Citation Analysis]
189 Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2022;57:60-9. [PMID: 34618619 DOI: 10.1080/00365521.2021.1984572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Armandi A, Actis GC, Ribaldone DG. Autoimmunity of the liver. Translational Autoimmunity 2022. [DOI: 10.1016/b978-0-12-824466-1.00012-1] [Reference Citation Analysis]
191 董 方. The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease. ACM 2022;12:11399-11404. [DOI: 10.12677/acm.2022.12121643] [Reference Citation Analysis]
192 Anand A, Singh AA, Elhence A, Vaishnav M, Biswas S, Gunjan D, Gamanagatti SR, Nayak B, Kumar R, Shalimar. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2022;12:362-71. [PMID: 35535086 DOI: 10.1016/j.jceh.2021.07.013] [Reference Citation Analysis]
193 Duvivier V, Creusot S, Broux O, Helbert A, Lesage L, Moreau K, Lesueur N, Gerard L, Lemaitre K, Provost N, Hubert EL, Baltauss T, Brzustowski A, De Preville N, Geronimi J, Adoux L, Letourneur F, Hammoutene A, Valla D, Paradis V, Delerive P. Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs. J Clin Exp Hepatol 2022;12:293-305. [PMID: 35535064 DOI: 10.1016/j.jceh.2021.09.001] [Reference Citation Analysis]
194 Georgescu CE. Polycystic ovary syndrome and nonalcoholic fatty liver disease. Polycystic Ovary Syndrome 2022. [DOI: 10.1016/b978-0-12-823045-9.00007-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Padole P, Arora A, Sharma P, Chand P, Verma N, Kumar A. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol 2022;12:435-9. [PMID: 35535066 DOI: 10.1016/j.jceh.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Gao W, Li Z, Chu H, Yuan H, Hu L, Yao L, Zhang L, Wang W, Lin R, Yang L. Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_6] [Reference Citation Analysis]
198 Rojas Á, Lara-romero C, Muñoz-hernández R, Gato S, Ampuero J, Romero-gómez M. Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology 2022;13:204201882211424. [DOI: 10.1177/20420188221142452] [Reference Citation Analysis]
199 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2022;37:7-14. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
200 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
201 Farooqui N, Elhence A, Shalimar. A Current Understanding of Bile Acids in Chronic Liver Disease. J Clin Exp Hepatol 2022;12:155-73. [PMID: 35068796 DOI: 10.1016/j.jceh.2021.08.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
202 Koeckerling D, Marjot T, Cobbold J. Non-alcoholic Fatty Liver Disease. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_7] [Reference Citation Analysis]
203 Geier A. Ein Ausblick in die Zukunft. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_38] [Reference Citation Analysis]
204 Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. J Gastroenterol 2022;57:357-71. [PMID: 35325295 DOI: 10.1007/s00535-022-01860-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
205 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
206 Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, Park SH, Lee MS, Kim DJ, Kim HS, Suk KT. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. Int J Mol Sci 2021;23:426. [PMID: 35008852 DOI: 10.3390/ijms23010426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
207 Cao S, Yang X, Zhang Z, Wu J, Chi B, Chen H, Yu J, Feng S, Xu Y, Li J, Zhang Y, Wang X, Wang Y. Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. Eur J Med Chem 2021;230:114089. [PMID: 34998040 DOI: 10.1016/j.ejmech.2021.114089] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
209 Fang Y, Hegazy L, Finck BN, Elgendy B. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. J Med Chem 2021;64:17545-71. [PMID: 34889100 DOI: 10.1021/acs.jmedchem.1c01017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
210 Zhang B, Kuipers F, de Boer JF, Kuivenhoven JA. Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. J Clin Med 2021;11:4. [PMID: 35011746 DOI: 10.3390/jcm11010004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
211 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
212 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
214 Abbas N, Quraishi MN, Trivedi P. Emerging drugs for the treatment of primary sclerosing cholangitis. Curr Opin Pharmacol 2021;62:23-35. [PMID: 34894541 DOI: 10.1016/j.coph.2021.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
215 Marchianò S, Biagioli M, Roselli R, Zampella A, Di Giorgio C, Bordoni M, Bellini R, Morretta E, Monti MC, Distrutti E, Fiorucci S. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB J 2022;36:e22060. [PMID: 34862975 DOI: 10.1096/fj.202101397R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Venkateswaran N, Weismiller S, Krok K. Recurrent NASH Post-liver Transplant: Implications and Treatment. Curr Hepatology Rep 2021;20:108-116. [DOI: 10.1007/s11901-021-00569-7] [Reference Citation Analysis]
217 Spinosa M, Wong S. Screening for Non-alcoholic Fatty Liver Disease in Current Practice. Curr Hepatology Rep 2021;20:128-134. [DOI: 10.1007/s11901-021-00577-7] [Reference Citation Analysis]
218 Jung Y, Koo BK, Jang SY, Kim D, Lee H, Lee DH, Joo SK, Jung YJ, Park JH, Yoo T, Choi M, Lee MK, Kang SW, Chang MS, Kim W, Hwang GS; Innovative Target Exploration of NAFLD (ITEN) consortium. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. Liver Int 2021;41:2892-902. [PMID: 34358397 DOI: 10.1111/liv.15030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
219 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
220 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
221 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
222 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
224 Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, Eisenberg D, Azagury DE, Ikramuddin S. ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. Surg Obes Relat Dis 2021:S1550-7289(21)00548-7. [PMID: 34953742 DOI: 10.1016/j.soard.2021.11.015] [Reference Citation Analysis]
225 Yenilmez B, Wetoska N, Kelly M, Echeverria D, Min K, Lifshitz L, Alterman JF, Hassler MR, Hildebrand S, DiMarzio C, McHugh N, Vangjeli L, Sousa J, Pan M, Han X, Brehm MA, Khvorova A, Czech MP. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol Ther 2021:S1525-0016(21)00578-5. [PMID: 34774753 DOI: 10.1016/j.ymthe.2021.11.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Hong T, Chen Y, Li X, Lu Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxid Med Cell Longev 2021;2021:6889533. [PMID: 34745420 DOI: 10.1155/2021/6889533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
227 Dashek RJ, Diaz C, Chandrasekar B, Rector RS. The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH. Front Endocrinol (Lausanne) 2021;12:770740. [PMID: 34745017 DOI: 10.3389/fendo.2021.770740] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
229 Mitsinikos T, Mrowczynski-Hernandez P, Kohli R. Pediatric Nonalcoholic Fatty Liver Disease. Pediatr Clin North Am 2021;68:1309-20. [PMID: 34736591 DOI: 10.1016/j.pcl.2021.07.013] [Reference Citation Analysis]
230 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
231 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
232 Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin CB, Loomba R. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2021;19:2274-2283.e5. [PMID: 32882428 DOI: 10.1016/j.cgh.2020.08.061] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
233 Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
234 Steinman JB, Salomao MA, Pajvani UB. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. Liver Int 2021;41:2534-46. [PMID: 34328687 DOI: 10.1111/liv.15025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
235 Li X, Ge J, Li Y, Cai Y, Zheng Q, Huang N, Gu Y, Han Q, Li Y, Sun R, Liu R. Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease. Acta Pharm Sin B 2021;11:3527-41. [PMID: 34900534 DOI: 10.1016/j.apsb.2021.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
236 Tran C, Kim JJ, Feld JJ, Wong WW. Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. CanLivJ 2021;4:360-9. [DOI: 10.3138/canlivj-2021-0011] [Reference Citation Analysis]
237 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
238 Muthiah MD, Ng CH, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Hao Tan DJ, Yong JN, Pan X, Heng Koh JW, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.. [DOI: 10.1101/2021.10.22.21265361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
240 Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT, Friedman SL. Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. Sci Rep 2021;11:20827. [PMID: 34675338 DOI: 10.1038/s41598-021-99008-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
241 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
242 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
243 Du K, Li S, Li C, Li P, Miao C, Luo T, Qiu B, Ding W. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater 2021;134:228-39. [PMID: 34265474 DOI: 10.1016/j.actbio.2021.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
244 Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells 2021;10:2759. [PMID: 34685739 DOI: 10.3390/cells10102759] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
245 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
246 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
247 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
248 Zhou F, Stueck A, Mcleod M. Liver biopsy complication rates in patients with non-alcoholic fatty liver disease. CanLivJ. [DOI: 10.3138/canlivj-2021-0019] [Reference Citation Analysis]
249 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
250 Poynard T, Paradis V, Mullaert J, Deckmyn O, Gault N, Marcault E, Manchon P, Si Mohammed N, Parfait B, Ibberson M, Gautier JF, Boitard C, Czernichow S, Larger E, Drane F, Castille JM, Peta V, Brzustowski A, Terris B, Vallet-Pichard A, Roulot D, Laouénan C, Bedossa P, Castera L, Pol S, Valla D; Quid-Nash consortium. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Aliment Pharmacol Ther 2021;54:952-66. [PMID: 34398492 DOI: 10.1111/apt.16543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
251 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
252 Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther 2021;15:3997-4009. [PMID: 34588764 DOI: 10.2147/DDDT.S315724] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
253 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol 2020;19:674-90. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 21.5] [Reference Citation Analysis]
254 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
255 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
256 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
257 Roeb E. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Visc Med 2021;37:273-80. [PMID: 34540943 DOI: 10.1159/000515445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
258 Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, Goldkind L, Di Bisceglie AM. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun 2021;12:5503. [PMID: 34535644 DOI: 10.1038/s41467-021-25701-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
259 Kostrzewski T, Snow S, Battle AL, Peel S, Ahmad Z, Basak J, Surakala M, Bornot A, Lindgren J, Ryaboshapkina M, Clausen M, Lindén D, Maass C, Young LM, Corrigan A, Ewart L, Hughes D. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol 2021;4:1080. [PMID: 34526653 DOI: 10.1038/s42003-021-02616-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
260 Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab 2021;4:e00296. [PMID: 34505423 DOI: 10.1002/edm2.296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
261 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
262 Biagioli M, Fiorucci S. Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research 2021;5:119-41. [DOI: 10.1016/j.livres.2021.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
263 Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021;176:113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
264 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 160] [Cited by in F6Publishing: 153] [Article Influence: 80.0] [Reference Citation Analysis]
265 Föh B, Sayk F, Marquardt JU. Neue Entwicklungen in der Diagnostik und Therapie der metabolisch assoziierten, nicht-alkoholischen Fettlebererkrankung. Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021;15:121-129. [DOI: 10.1055/a-1491-5792] [Reference Citation Analysis]
266 Luo M, Xu H, Dong Y, Shen K, Lu J, Yin Z, Qi M, Sun G, Tang L, Xiang J, Deng Z, Dickschat JS, Sun Y. Der Mechanismus von dehydatisierenden Bimodulen in der trans ‐Acyltransferase‐Polketidbiosynthese: Eine Modellstudie am hepatoprotektiven Hangtaimycin. Angewandte Chemie 2021;133:19288-19292. [DOI: 10.1002/ange.202106250] [Reference Citation Analysis]
267 Zhou T, Kundu D, Robles-Linares J, Meadows V, Sato K, Baiocchi L, Ekser B, Glaser S, Alpini G, Francis H, Kennedy L. Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease. Cells 2021;10:2072. [PMID: 34440841 DOI: 10.3390/cells10082072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
268 Ratziu V. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. Clin Liver Dis (Hoboken) 2021;17:398-400. [PMID: 34386202 DOI: 10.1002/cld.1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
270 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021;70:1570-9. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
271 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 24.5] [Reference Citation Analysis]
272 Cox B, Trasolini R, Galts C, Yoshida EM, Marquez V. Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease. CanLivJ 2021;4:275-82. [DOI: 10.3138/canlivj-2021-0004] [Reference Citation Analysis]
273 Geerts A, Lefere S. The Role of Bariatric Surgery in Fatty Liver. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.96975] [Reference Citation Analysis]
274 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
275 Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract 2021;2021:6612892. [PMID: 34326871 DOI: 10.1155/2021/6612892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
277 Evangelakos I, Heeren J, Verkade E, Kuipers F. Role of bile acids in inflammatory liver diseases. Semin Immunopathol 2021. [PMID: 34236487 DOI: 10.1007/s00281-021-00869-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
278 Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, Smith ND, Chen HC, Lawitz EJ. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol 2021;75:25-33. [PMID: 33581174 DOI: 10.1016/j.jhep.2021.01.047] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 17.5] [Reference Citation Analysis]
279 Kremoser C. FXR agonists for NASH: How are they different and what difference do they make? J Hepatol 2021;75:12-5. [PMID: 33985820 DOI: 10.1016/j.jhep.2021.03.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
280 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
281 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
282 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 23.5] [Reference Citation Analysis]
283 Zhu N, Huang S, Zhang Q, Zhao Z, Qu H, Ning M, Leng Y, Liu J. Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. Metabolites 2021;11:374. [PMID: 34200685 DOI: 10.3390/metabo11060374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Bagriy AE, Zubov AD, Khomenko MV, Mikhailichenko ES, Pylaeva EA, Khaustova NA, Bryukhovetskaya EV. Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2021;31:14-26. [DOI: 10.22416/1382-4376-2021-31-2-14-26] [Reference Citation Analysis]
285 Davison BA, Edwards C, Loomba R, Harrison SA, Cotter G, Alkhouri N, Koch GG, Dittrich HC. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. JGH Open 2021;5:740-9. [PMID: 34263067 DOI: 10.1002/jgh3.12575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
286 Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [PMID: 33589830 DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 29.0] [Reference Citation Analysis]
287 Liu D, Wong CC, Zhou Y, Li C, Chen H, Ji F, Go MYY, Wang F, Su H, Wei H, Cai Z, Wong N, Wong VWS, Yu J. Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target. Gastroenterology 2021;160:2467-2482.e3. [PMID: 33647280 DOI: 10.1053/j.gastro.2021.02.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
288 Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol 2021;74:1442-54. [PMID: 33631228 DOI: 10.1016/j.jhep.2021.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
289 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 51.5] [Reference Citation Analysis]
290 Li S, Wang C, Zhang X, Su W. Cytochrome P450 Omega-Hydroxylase 4a14 Attenuates Cholestatic Liver Fibrosis. Front Physiol 2021;12:688259. [PMID: 34135776 DOI: 10.3389/fphys.2021.688259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
291 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
293 Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver 2021;15:451-8. [PMID: 33431715 DOI: 10.5009/gnl20218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
294 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
295 Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 2020;28:233-44. [PMID: 32791115 DOI: 10.1016/j.chom.2020.07.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 27.5] [Reference Citation Analysis]
296 Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, Ruane P, Shiffman ML, Sheikh A, Gunn N, Caldwell SH, Huss RS, Myers RP, Wai-Sun Wong V, Alkhouri N, Goodman Z, Loomba R. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatol Commun 2021;5:1201-11. [PMID: 34278169 DOI: 10.1002/hep4.1710] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
297 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
298 Khanam A, Saleeb PG, Kottilil S. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? Cells 2021;10:1097. [PMID: 34064375 DOI: 10.3390/cells10051097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
299 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
300 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 24.0] [Reference Citation Analysis]
301 Sciarrillo CM, Keirns BH, Koemel NA, Anderson KL, Emerson SR. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. Liver Int 2021;41:894-904. [PMID: 33506572 DOI: 10.1111/liv.14802] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
302 Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol 2021;18:335-47. [PMID: 33568795 DOI: 10.1038/s41575-020-00404-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 40.0] [Reference Citation Analysis]
303 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
304 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. [PMID: 33283415 DOI: 10.1111/liv.14749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
305 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
306 Koutoukidis DA, Morris E, Henry JA, Shammoon Y, Zimmerman M, Michalopoulou M, Jebb SA, Aveyard P. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLoS One 2021;16:e0250385. [PMID: 33882107 DOI: 10.1371/journal.pone.0250385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
308 Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput Struct Biotechnol J 2021;19:2148-59. [PMID: 33995909 DOI: 10.1016/j.csbj.2021.04.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
309 Yang X, Delsante M, Daneshpajouhnejad P, Fenaroli P, Mandell KP, Wang X, Takahashi S, Halushka MK, Kopp JB, Levi M, Rosenberg AZ. TAZ/TEAD complex regulates TGF-β1-mediated fibrosis in iPSC-derived renal organoids.. [DOI: 10.1101/2021.04.15.440011] [Reference Citation Analysis]
310 Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol 2021;12:660179. [PMID: 33936094 DOI: 10.3389/fimmu.2021.660179] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
311 Xanthakos SA. Pharmacological, Endoscopic, Metabolic, and Surgical Procedures for Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;17:209-14. [PMID: 33868667 DOI: 10.1002/cld.1030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. J Pers Med 2021;11:281. [PMID: 33917196 DOI: 10.3390/jpm11040281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
313 Hagström H, Bu D, Nasr P, Ekstedt M, Hegmar H, Kechagias S, Zhang N, An Z, Stål P, Scherer PE. Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scand J Gastroenterol 2021;56:437-42. [PMID: 33556256 DOI: 10.1080/00365521.2021.1879249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
314 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
315 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
316 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines 2021;9:365. [PMID: 33807461 DOI: 10.3390/biomedicines9040365] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
317 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
318 Huisman TM, Dieterich DT, Friedman SL. Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. J Exp Pharmacol 2021;13:329-38. [PMID: 33776490 DOI: 10.2147/JEP.S265286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
319 Werge MP, McCann A, Galsgaard ED, Holst D, Bugge A, Albrechtsen NJW, Gluud LL. The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:1081. [PMID: 33807699 DOI: 10.3390/jcm10051081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
320 Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2021;36:629-36. [PMID: 32627871 DOI: 10.1111/jgh.15172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
321 Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Massault PP, Scatton O, Vaillant JC, Morozov VA, Pol S, Lagaye S. Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs. World J Hepatol 2021; 13(2): 187-217 [PMID: 33708350 DOI: 10.4254/wjh.v13.i2.187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
322 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 18.5] [Reference Citation Analysis]
323 Sanyal AJ, Ling L, Beuers U, DePaoli AM, Lieu HD, Harrison SA, Hirschfield GM. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Rep 2021;3:100255. [PMID: 33898959 DOI: 10.1016/j.jhepr.2021.100255] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
324 Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Curr Hepatol Rep. 2020;19:315-326. [PMID: 33585157 DOI: 10.1007/s11901-020-00530-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
325 Helmstädter M, Vietor J, Sommer J, Schierle S, Willems S, Kaiser A, Schmidt J, Merk D. A New FXR Ligand Chemotype with Agonist/Antagonist Switch. ACS Med Chem Lett 2021;12:267-74. [PMID: 33603974 DOI: 10.1021/acsmedchemlett.0c00647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
326 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
327 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
328 Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail 2021;8:789-98. [PMID: 33534958 DOI: 10.1002/ehf2.13222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
329 Irvine KM, Okano S, Patel PJ, Horsfall LU, Williams S, Russell A, Powell EE. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2021;11:2858. [PMID: 33536476 DOI: 10.1038/s41598-021-82315-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
330 Jansen PLM. Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease. Hepatol Int 2021;15:283-6. [PMID: 33523348 DOI: 10.1007/s12072-021-10134-5] [Reference Citation Analysis]
331 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
332 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
333 Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology 2021;73:625-43. [PMID: 33169409 DOI: 10.1002/hep.31622] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 41.0] [Reference Citation Analysis]
334 Kedarisetty CK, Bhardwaj A, Kumar G, Rastogi A, Bihari C, Kumar M, Sarin SK. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study. Indian J Gastroenterol 2021;40:41-9. [PMID: 33772456 DOI: 10.1007/s12664-020-01131-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
335 Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V, Romero-Gómez M, Tacke F, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? JHEP Rep 2021;3:100234. [PMID: 33733078 DOI: 10.1016/j.jhepr.2021.100234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
336 Maevskaya MM. Features of the therapy of non-alcoholic fatty liver disease in comorbid patients. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2020-21-136-143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
337 Sohail MI, Dönmez-Cakil Y, Szöllősi D, Stockner T, Chiba P. The Bile Salt Export Pump: Molecular Structure, Study Models and Small-Molecule Drugs for the Treatment of Inherited BSEP Deficiencies. Int J Mol Sci 2021;22:E784. [PMID: 33466755 DOI: 10.3390/ijms22020784] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
338 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
339 Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, Birkel M, Brusilovskaya K, Königshofer P, Peck-Radosavljevic M, Watkins WJ, Trauner M, Breckenridge DG, Kremoser C, Reiberger T. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines 2021;9:60. [PMID: 33435509 DOI: 10.3390/biomedicines9010060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
340 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
341 Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun 2021;5:573-88. [PMID: 33860116 DOI: 10.1002/hep4.1657] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
342 Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ 2021;12:1. [PMID: 33397443 DOI: 10.1186/s13293-020-00344-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
343 Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, Johnson RJ, Jensen T. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22:351-66. [PMID: 33389543 DOI: 10.1007/s11154-020-09621-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
344 Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol 2021;18:85-6. [PMID: 33420415 DOI: 10.1038/s41575-020-00406-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
345 Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:219-231.e1. [PMID: 32781086 DOI: 10.1053/j.gastro.2020.08.004] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 51.5] [Reference Citation Analysis]
346 Mathurin P, Dharancy S, Lassailly G. Obésité et foie. Les Obésités 2021. [DOI: 10.1016/b978-2-294-76753-1.00050-3] [Reference Citation Analysis]
347 Maroni L, Fianchi F, Miele L, Svegliati Baroni G. The pathophysiology of gut–liver connection. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes 2021. [DOI: 10.1016/b978-0-12-821927-0.00002-4] [Reference Citation Analysis]
348 Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, Watt KD, Port JD, Basu R, Acosta A, Hanouneh I, Gara N, Shah M, Mundi M, Clark M, Grothe K, Storm AC, Levy MJ, Abu Dayyeh BK. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021;19:146-154.e4. [PMID: 32360804 DOI: 10.1016/j.cgh.2020.04.068] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 23.0] [Reference Citation Analysis]
349 Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167 [PMID: 33442452 DOI: 10.4254/wjh.v12.i12.1258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
350 Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Mol Metab 2021;46:101153. [PMID: 33359400 DOI: 10.1016/j.molmet.2020.101153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
351 Henriksson E, Andersen B. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front Endocrinol (Lausanne) 2020;11:601349. [PMID: 33414764 DOI: 10.3389/fendo.2020.601349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
352 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
353 Grzych G, Chávez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M, Legry V, Verkindt H, Raverdy V, Legendre B, Caiazzo R, Van Gaal L, Goossens JF, Paumelle R, Francque S, Pattou F, Haas JT, Tailleux A, Staels B. NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Rep 2021;3:100222. [PMID: 33615207 DOI: 10.1016/j.jhepr.2020.100222] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
354 Raikhelson KL, Kondrashina EA, Pazenko EV. [Mixed steatohepatitis: more questions than answers (Part 1)]. Ter Arkh 2020;92:91-6. [PMID: 33720580 DOI: 10.26442/00403660.2020.12.200470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
356 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]
357 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
358 Lu P, Yang G, Jiang L, He W, Wu W, Qi L, Shen S, Rao J, Zhang P, Xue Z, Jiang C, Fan G, Zhu X. Characterizing disease progression of nonalcoholic steatohepatitis in Leptin-deficient rats by integrated transcriptome analysis. Exp Biol Med (Maywood) 2021;246:678-87. [PMID: 33302736 DOI: 10.1177/1535370220976530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
359 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
360 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
361 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
362 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 20.0] [Reference Citation Analysis]
363 Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep 2020;10:21117. [PMID: 33273703 DOI: 10.1038/s41598-020-78342-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
364 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
365 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
366 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
367 Krishnarao A, Punzalan CS. National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease. Curr Hepatology Rep 2020;19:429-436. [DOI: 10.1007/s11901-020-00552-8] [Reference Citation Analysis]
368 Schattenberg JM. Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visc Med 2020;36:411-6. [PMID: 33251276 DOI: 10.1159/000507231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
369 Horn CL, Ta AC, Gunn NT. Current and Emerging Treatments for Non-alcoholic Steatohepatitis. Curr Hepatology Rep 2020;19:391-401. [DOI: 10.1007/s11901-020-00540-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
370 Pierantonelli I, Lioci G, Gurrado F, Giordano DM, Rychlicki C, Bocca C, Trozzi L, Novo E, Panera N, De Stefanis C, D'Oria V, Marzioni M, Maroni L, Parola M, Alisi A, Svegliati-Baroni G. HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation. Liver Int 2020;40:3127-39. [PMID: 33098723 DOI: 10.1111/liv.14712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
371 Jindal A, Sarin SK. Letter to the Editor: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective? Hepatology 2020;72:2240-1. [PMID: 32488894 DOI: 10.1002/hep.31400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
372 Le L, Kullar R, Saleh HM, Saab S. Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. Dig Dis Sci 2020;65:3719-25. [PMID: 32671584 DOI: 10.1007/s10620-020-06382-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Patel K, Chung C, Myers RP. Reply. Hepatology 2020;72:2241-2. [PMID: 32490551 DOI: 10.1002/hep.31402] [Reference Citation Analysis]
374 Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, Weeks TL, Alkhouri N, Zein N, Tang WHW, Fischbach MA, Brown JM, Allayee H, Dasarathy S, Gogonea V, Hazen SL. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism 2021;116:154457. [PMID: 33275980 DOI: 10.1016/j.metabol.2020.154457] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
375 Trivedi P, Wang S, Friedman SL. The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells. Cell Metab 2021;33:242-57. [PMID: 33232666 DOI: 10.1016/j.cmet.2020.10.026] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 18.7] [Reference Citation Analysis]
376 Patanwala I, Molnar LE, Akerboom K, Lane KE. Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with non-alcoholic fatty liver disease. Frontline Gastroenterol 2021;12:557-63. [PMID: 34917312 DOI: 10.1136/flgastro-2020-101669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
377 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
378 Furuta K, Guo Q, Hirsova P, Ibrahim SH. Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis. Biology (Basel) 2020;9:E395. [PMID: 33198153 DOI: 10.3390/biology9110395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
379 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
380 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
381 Li X, Wang J, Gong X, Zhang M, Kang S, Shu B, Wei Z, Huang ZS, Li D. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res 2020;48:8255-68. [PMID: 32710621 DOI: 10.1093/nar/gkaa615] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
382 Stine JG, Xu D, Schmitz K, Sciamanna C, Kimball SR. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Dig Dis Sci 2020;65:3238-43. [PMID: 32239376 DOI: 10.1007/s10620-020-06226-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
383 Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology 2020;72:1819-37. [PMID: 32740969 DOI: 10.1002/hep.31491] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
384 Zhou B, Jia L, Zhang Z, Xiang L, Yuan Y, Zheng P, Liu B, Ren X, Bian H, Xie L, Li Y, Lu J, Zhang H, Lu Y. The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36. Adv Sci (Weinh) 2020;7:2002273. [PMID: 33173745 DOI: 10.1002/advs.202002273] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
385 Stokman G, van den Hoek AM, Denker Thorbekk D, Pieterman EJ, Skovgård Veidal S, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver Int 2020;40:2860-76. [PMID: 32841505 DOI: 10.1111/liv.14643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
386 Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY) 2020;45:3507-22. [PMID: 32761254 DOI: 10.1007/s00261-020-02684-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
387 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
388 Ziogas IA, Zapsalis K, Giannis D, Tsoulfas G. Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!. World J Hepatol 2020; 12(10): 709-721 [PMID: 33200011 DOI: 10.4254/wjh.v12.i10.709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
389 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
390 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
391 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
392 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
393 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
394 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 60] [Cited by in F6Publishing: 76] [Article Influence: 20.0] [Reference Citation Analysis]
395 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
396 T SK, B LK, T SS. WOMEN IN THE AGE GROUP OF 20 TO 50 YEARS ARE LESS PRONE TO DEVELOP NAFLD IN KERALA, SOUTH INDIA: A POPULATION BASED STUDY. IJAR 2020. [DOI: 10.36106/ijar/6000585] [Reference Citation Analysis]
397 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 176] [Cited by in F6Publishing: 199] [Article Influence: 58.7] [Reference Citation Analysis]
398 Alsawat K, Hashim A, Alboraie M, Fouad Y. Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion. J Clin Transl Hepatol 2020;8:354-5. [PMID: 33083259 DOI: 10.14218/JCTH.2020.00049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
399 Kim YS, Kim SG. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. Clin Mol Hepatol 2020;26:715-27. [PMID: 32951410 DOI: 10.3350/cmh.2020.0173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
400 Zou ZY, Fan JG. Percutaneous liver biopsy: another option of hepatic sample collection approach in single-cell sequencing studies? Ann Transl Med 2020;8:1033. [PMID: 32953833 DOI: 10.21037/atm.2020.04.23] [Reference Citation Analysis]
401 Schäfer-Korting M, Zoschke C. How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development. Handb Exp Pharmacol 2021;265:29-56. [PMID: 32894342 DOI: 10.1007/164_2020_374] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
402 Herrema H, Niess JH. Intestinal microbial metabolites in human metabolism and type 2 diabetes. Diabetologia 2020;63:2533-47. [PMID: 32880688 DOI: 10.1007/s00125-020-05268-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
403 Pützer J, Kahl S. Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes. Diabetologe 2020;16:574-583. [DOI: 10.1007/s11428-020-00649-0] [Reference Citation Analysis]
404 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 36.0] [Reference Citation Analysis]
405 Sheka AC, Hameed B, Ikramuddin S. Nonalcoholic Steatohepatitis-Reply. JAMA 2020;324:899-900. [PMID: 32870294 DOI: 10.1001/jama.2020.10437] [Reference Citation Analysis]
406 Malnick S, Somin M. Clinical endpoints are necessary in the interim analysis of REGENERATE. The Lancet 2020;396:663. [DOI: 10.1016/s0140-6736(20)30810-2] [Reference Citation Analysis]
407 Zampaglione L, Ferrari J, Goossens N. La stéatopathie dysmétabolique. Schweiz Gastroenterol 2020;1:79-85. [DOI: 10.1007/s43472-020-00018-8] [Reference Citation Analysis]
408 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 190] [Cited by in F6Publishing: 165] [Article Influence: 63.3] [Reference Citation Analysis]
409 Xu G, Song M. Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. Surg Obes Relat Dis. 2021;17:231-238. [PMID: 33036939 DOI: 10.1016/j.soard.2020.08.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
410 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
411 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
412 Li C, Yang J, Wang Y, Qi Y, Yang W, Li Y. Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Front Pharmacol 2020;11:1247. [PMID: 32982723 DOI: 10.3389/fphar.2020.01247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
413 Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021;14:11-9. [PMID: 32583961 DOI: 10.1111/cts.12839] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
414 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
415 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
416 Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, Yamauchi N, Ushiku T, Moriya K, Yotsuyanagi H, Koike K. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet. PLoS One 2020;15:e0234750. [PMID: 32785220 DOI: 10.1371/journal.pone.0234750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
417 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
418 Hofmann WP, Buggisch P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, Felten G, Heyne R, Ingiliz P, Schmidt A, Stein K, Wedemeyer H, Berg T, Wiegand J, Lammert F, Zeuzem S, Schattenberg JM. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.JHEP Rep. 2020;2:100168. [PMID: 32964201 DOI: 10.1016/j.jhepr.2020.100168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
419 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
420 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
421 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
422 Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab 2021;50:101049. [PMID: 32673798 DOI: 10.1016/j.molmet.2020.101049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
423 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
424 Yari Z, Cheraghpour M, Alavian SM, Hedayati M, Eini-Zinab H, Hekmatdoost A. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. Eur J Clin Nutr 2021;75:99-111. [PMID: 32647367 DOI: 10.1038/s41430-020-0679-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
425 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
426 Bajaj JS, Brenner DM, Cai Q, Cash BD, Crowell M, DiBaise J, Gallegos-Orozco JF, Gardner TB, Gyawali CP, Ha C, Holtmann G, Jamil LH, Kaplan GG, Karsan HA, Kinoshita Y, Lebwohl B, Leontiadis GI, Lichtenstein GR, Longstreth GF, Muthusamy VR, Oxentenko AS, Pimentel M, Pisegna JR, Rubenstein JH, Russo MW, Saini SD, Samadder NJ, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy BE. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [PMID: 32618649 DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
427 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
428 Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol 2020;73:9-11. [PMID: 32360996 DOI: 10.1016/j.jhep.2020.04.034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
429 Oeda S, Takahashi H, Imajo K, Seko Y, Kobayashi T, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Irie H, Sueoka E, Aishima S, Kage M, Itoh Y, Eguchi Y, Nakajima A. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. Hepatol Res 2020;50:831-9. [PMID: 32337818 DOI: 10.1111/hepr.13508] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
430 Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology 2020;72:58-71. [PMID: 32115759 DOI: 10.1002/hep.31205] [Cited by in Crossref: 139] [Cited by in F6Publishing: 128] [Article Influence: 46.3] [Reference Citation Analysis]
431 Hoofnagle JH. FXR Agonists as Therapy for Liver Disease. Hepatology 2020;72:1-3. [PMID: 32275777 DOI: 10.1002/hep.31265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
432 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
433 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun 2020;4:1293-301. [PMID: 32923833 DOI: 10.1002/hep4.1541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
434 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
435 Micheli L, Pacini A, Di Cesare Mannelli L, Trallori E, D'Ambrosio R, Bianchini C, Lampertico P, Ghelardini C. Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation. Nutrients 2020;12:E1819. [PMID: 32570937 DOI: 10.3390/nu12061819] [Reference Citation Analysis]
436 Chang Y, Li H. Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success? J Clin Transl Hepatol 2020;8:222-9. [PMID: 32832403 DOI: 10.14218/JCTH.2020.00026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
437 Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 2020;55:706-11. [PMID: 32476514 DOI: 10.1080/00365521.2020.1766554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
438 Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int 2020;40:1254-61. [PMID: 32301554 DOI: 10.1111/liv.14478] [Cited by in Crossref: 146] [Cited by in F6Publishing: 141] [Article Influence: 48.7] [Reference Citation Analysis]
439 Schulte-frohlinde E. Die verfettete Leber in der Hausarztpraxis. MMW - Fortschritte der Medizin 2020;162:58-60. [DOI: 10.1007/s15006-020-0618-1] [Reference Citation Analysis]
440 Hagström H. Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Aliment Pharmacol Ther 2020;51:1204-5. [PMID: 32424917 DOI: 10.1111/apt.15744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, Broder A, Ahmed A. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8:215-221. [PMID: 32832402 DOI: 10.14218/jcth.2020.00014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
442 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
443 Zhu Y, Xu S, Lu Y, Wei Y, Yao B, Guo F, Zheng X, Wang Y, He Y, Jin L, Li Y. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol 2020;11:590. [PMID: 32477115 DOI: 10.3389/fphar.2020.00590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
444 Malnick S, Mildiner S, Neuman MG. Obeticholic acid for treatment of NAFLD—A drug in search of a disease. GastroHep 2020;2:133-137. [DOI: 10.1002/ygh2.397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
445 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. [PMID: 32353039 DOI: 10.1371/journal.pmed.1003100] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 32.0] [Reference Citation Analysis]
446 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
447 Weaver MJ, McHenry SA, Sayuk GS, Gyawali CP, Davidson NO. Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes. Hepatol Commun. 2020;4:493-503. [PMID: 32258945 DOI: 10.1002/hep4.1485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
448 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
449 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 198] [Cited by in F6Publishing: 218] [Article Influence: 66.0] [Reference Citation Analysis]
450 Ratziu V. Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. Hepatology 2020;71:1146-9. [PMID: 32118303 DOI: 10.1002/hep.31213] [Reference Citation Analysis]
451 Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int 2020;40:736-50. [PMID: 31997561 DOI: 10.1111/liv.14390] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 21.7] [Reference Citation Analysis]
452 Strathearn LS, Stepanov AI, Font-Burgada J. Inflammation in Primary and Metastatic Liver Tumorigenesis-Under the Influence of Alcohol and High-Fat Diets. Nutrients 2020;12:E933. [PMID: 32230953 DOI: 10.3390/nu12040933] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
453 Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020;9:E590. [PMID: 32131439 DOI: 10.3390/cells9030590] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
454 Hindson J. Obeticholic acid for the treatment of NASH. Nat Rev Gastroenterol Hepatol 2020;17:66. [PMID: 31919473 DOI: 10.1038/s41575-020-0264-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
455 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
456 Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ. New drugs for non-alcoholic steatohepatitis. Liver Int 2020;40 Suppl 1:96-101. [PMID: 32077615 DOI: 10.1111/liv.14354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
457 Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat Commun 2020;11:240. [PMID: 31932588 DOI: 10.1038/s41467-019-14138-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 13.7] [Reference Citation Analysis]
458 Zhu C, Claudel T, Trauner M. Bile Acids and Bilirubin in Liver Immunology. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_7] [Reference Citation Analysis]
459 Kohut T, Robbins J, Prout E, Katz L, Brothers J, Vazquez-diaz S, Genuario K, Panganiban J. Obesity in Children/Adolescents and Obesity-Related Comorbidities. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_27] [Reference Citation Analysis]
460 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
461 Kawaguchi-suzuki M. Nonalcoholic Fatty Liver Disease. PharmacotherapyFirst: A Multimedia Learning Resource 2017. [DOI: 10.21019/pharmacotherapyfirst.nafld_overview] [Reference Citation Analysis]